A review of the federal guidelines that inform and influence relationships between physicians and industry

Academic Emergency Medicine

Volumn 16, Issue 8, 2009, Pages 776-781

  Birkhahn, Robert H ^a   Jauch, Edward ^b   Kramer, David A ^c   Nowak, Richard M ^d   Raja, Ali S ^e   Summers, Richard L ^f   Weber, Jim Edward ^g,h   Diercks, Deborah B ⁱ  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c YORK HOSPITAL   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h HURLEY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fraud; Industry relations; Office of the inspector general; Pharmaceutical

Indexed keywords

DRUG INDUSTRY; EMERGENCY WARD; FUNDING; GOVERNMENT; HEALTH CARE; HUMAN; MEDICAL EDUCATION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; GUIDELINES AS TOPIC; HUMANS; INDUSTRY; INTERPROFESSIONAL RELATIONS; PHYSICIANS; UNITED STATES;

EID: 68149182288     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1553-2712.2009.00460.x     Document Type: Review

References (24)

1. Anonymous. Gifts to physicians from industry. JAMA. 1991; 266:61-63
2. Office of the Inspector General. Compliance Program Guidance for Pharmaceutical Manufacturers. Available at: http://www.oig.hhs.gov/fraud/docs/ complianceguidance/042803pharmacymfgnonfr.pdf. Accessed May 7, 2009.
3. Food and Drug Administration. Final Compliance Program for Pharmaceutical Manufacturers. Available at: http://oig.hhs.gov/authorities/docs/03/ 050503FRCPGPharmac.pdf.
4. Kusserow R. Promotion of Prescription Drugs through Payments and Gifts. Available at: http:// www.oig.hhs.gov/oei/reports/oei-01-90-00480.pdf. Accessed May 7, 2009.
5. Office of the Inspector General. Medicare and State Health Programs: Fraud and Abuse; OIG Anti- Kickback Provisions. Available at: http://www.oig. hhs.gov/fraud/docs/safeharborregulations/ 072991.htm. Accessed May 7, 2009.
6. Office of the Inspector General. Advisory Opinion 04-103 Available at: http://www.oig.hhs.gov/fraud/ docs/advisoryopinions/2004/ao0403.pdf. Accessed May 7, 2009.
7. Office of the Inspector General. Advisory Opinion 08-102 Available at: http://www.oig.hhs.gov/fraud/ docs/advisoryopinions/2008/AdvOpn08-02A.pdf. Accessed May 7, 2009.
8. Statement of William H. Jordan, Senior Counsel to the Assistant Attorney General, Civil Division, U.S Department of Justice, in House Committee on Ways and Means. 2003: Washington DC. Available at: http://waysandmeans.house.gov/ hearings.asp? formmode=view&id=677. Accessed May 7, 2009.
9. Demske GE. Examining the Relationship between the Medical Device Industry and Physicians. In: Senate Special Committee on Aging. Washington DC: 2008, pp 1-10. Available at: http://www.oig. hhs.gov/testimony/docs/2008/demske-testimony 022708.pdf. Accessed May 7, 2009.
10. U.S. Department of Justice. Fraud Statistics 1986-2008. Available at: http://www.taf.org/FCA-stats-DoJ-2008.pdf. Accessed May 7, 2009.
11. Office of Inspector General. Federal Register, Title 42 Public Health, Chapter V. 42 CFR 1001.952 Exceptions. Available at: http://frwebgate.access. gpo.gov/cgi-bin/get-cfr.cgi?TITLE=42&PART=1001& SECTION=952&YEAR= 2001&TYPE=TEXT. Accessed May 7, 2009.
12. United States v. TAP Pharmaceuticals, sentencing memorandum of the United States (Dec. 14, 2001), Criminal Action No. 01-CR-10354-WGY.
13. PhRMA. PhRMA Code on Interactions with Healthcare Professionals. Available at: http://www.phrma. org/code-on-interactions-with-healthcare- professionals/. Accessed May 7, 2009.
14. Accreditation Council for Continuing Medical Education. Standards for Commercial Support of Continuing Medical Education. Available at: http:// www.accme.org/dir-docs/doc-upload/68b2902afb73- 44d1-8725-80a1504e520c- uploaddocument.pdf. Accessed May 7, 2009.
15. Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry-self-regulation in the shadow of federal prosecution. N Engl J Med. 2004; 351:1891-1900
16. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007; 297:1216-1223 (Pubitemid 46469916)
17. Ross JS, Nazem AG, Lurie P, Lackner JE, Krumholz HM. Updated estimates of pharmaceutical company payments to physicians in Vermont. JAMA. 2008; 300:1998-2000.
18. Steinbrook R. Disclosure of industry payments to physicians. N Engl J Med. 2008; 359:559-561
19. Feder B. New focus of inquiry into bribes: doctors. The New York Times, 2008. Available at: http://www. schlesingerlaw.com/News/032208-DoctorBribes.pdf. Accessed May 7, 2009.
20. Hirschler B, Kamalakraran A. Lawsuit claims Pfizer massaged Neurontin studies. Thomson Reuters, 2008. Available at: http://www.reuters.com/article/ healthNews/idUSTRE49746M20081008. Accessed May 7, 2009.
21. United States v. Ross A. Caputo and Robert M. Riley, appeals from the US District Court for the Northern District of Illinois (Feb 27, 2008), No.03 CR 126.
22. Yancy CW, Krum H, Massie BM, et al. The second follow-up serial infusions of nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Am Heart J, 2007; 153:478-484 (Pubitemid 46442809)
23. Accreditation Council for Continuing Medical Education. ACCME Annual Report Data 2006. Available at: http://www.accme.org/dir-docs/doc-upload/f5 1ed7d8-e3b4-479a-a9d8-57b6efedc27a-uploaddocument. pdf. Accessed May 7, 2009.
24. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006; 295:429-433 (Pubitemid 43144979)